Navigation Links
Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
Date:1/6/2009

use, and reduced opioid-related adverse events compared to the gold standard pain medication.

Pacira is seeking a co-promotion partner for EXPAREL in the United States. Outside the United States (except Japan), EXPAREL is available for licensing in both human and animal health applications. In the United States, Pacira intends to commercialize EXPAREL and its proprietary pipeline products within specialty acute care. Partnerships in the U.S. for both human and animal health to expand the commercialization are currently in development. EXPAREL is the latest product to benefit from Pacira's proprietary sustained-release DepoFoam(R) technology. DepoFoam technology is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. It achieves this by encapsulating the drug in multivesicular liposomal particles which then release the drug over a desired period of time without altering the drug molecule. DepoFoam is a proven technology that is already used in two commercially available products in the U.S. and Europe.

About Pacira

Pacira Pharmaceuticals, Inc. is an acute care specialty pharmaceutical company founded in March, 2007 through the acquisition of the former SkyePharma PLC injectable business, for which an experienced management team was assembled to address the needs of the acute care market. The company's most advanced product, EXPAREL(TM) (DepoBupivacaine), a bupivacaine-based product intended to deliver postoperative pain relief by infiltration, is in late Phase III clinical development. Pacira also plans to study EXPAREL for nerve block, non-surgical pain such as long bone fracture and for intraarticular injection. EXPAREL benefits from the proprietary DepoFoam Technology owned by Pacira. Two other DepoFoam-based products -- DepoDur(R) and DepoCyt/DepoCyte(R) -- are marketed by partners in several global territories. The Depo
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...  Teradata (NYSE: TDC ), the ... company, today announced the newest analytic innovation ... Life Sciences helps organizations integrate and analyze data ... (RED), clinical analysis, Real-World Evidence (RWE), and finance. ... can benefit by bringing safer, more effective treatments ...
(Date:4/20/2015)... , April 20, 2015 Pharmaceutical Research and ... $51.2 billion last year in the research and development ... represents the majority of all biopharmaceutical R&D spending – ... United States . The new R&D numbers, the ... are highlighted in the newly released PhRMA ...
(Date:4/20/2015)... Ill. , April 20, 2015  U.S. pharmacy cost ... expected to drift into the low double-digits by 2016, according ... talent, retirement and health solutions business of Aon plc ... design changes are projected to be 9.5 percent in 2015 ... Aon Hewitt predicts a similar rate of increase ...
Breaking Medicine Technology:Teradata Delivers Big Analytics Innovation for Life Sciences 2Teradata Delivers Big Analytics Innovation for Life Sciences 3Teradata Delivers Big Analytics Innovation for Life Sciences 4PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 2PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 4
... Laboratories, Inc. (OTCBB: UGNE), a leader in ... therapeutics, today announced the Company,s Vice President of ... presenting at IBC,s 4th Annual AsiaTIDES Oligonucleotide and ... Hotel in Tokyo, Japan. The TIDES ...
... DIEGO, Feb. 27, 2012 Optimer Pharmaceuticals, Inc. (NASDAQ: ... and fiscal year 2011 financial results and provide a ... the NASDAQ Global Market closes on March 7th.  The ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). ...
Cached Medicine Technology:Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference 2Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference 3Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results 2
(Date:4/20/2015)... April 21, 2015 The National ... Binau, Founder of Soul Care Group, Inc., as ... is recognized with this prestigious distinction for leadership in ... Local Chapters, NAPW is the nation's leading networking organizaiton ... Susan with our Woman of the Year Award,” says ...
(Date:4/20/2015)... 20, 2015 Global Lyme Alliance (GLA) ... last Saturday at the Hyatt Regency Greenwich, raised over ... Lyme and other debilitating tick-borne diseases. , “We ... and families who made this year’s Gala such a ... advancing research and education initiatives to ultimately find a ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Saint Joseph Regional ... 15 Top Health Systems by Truven Health Analytics, a leading ... quality of healthcare. SJRMC has been recognized by Truven Health ... the past four years. , According to Truven Health Analytics' ... Health Systems, in matchups with their peers, set the standard ...
(Date:4/20/2015)... Mauritius is a seemingly idyllic and tranquil island oasis ... miles) off the southeastern coast of Africa, the tiny ... where everyone lives together in harmony. , But the ... with drug abuse. In fact, it carries a dubious ... nation in eastern Africa. , “Many youngsters, they know ...
(Date:4/20/2015)... A recent cross-sectional survey involving ... the top 10 most beneficial therapies for fibromyalgia, no drugs ... harmful therapies, only approved drugs were named. , “The ... their effect is only felt as long as the patient ... interview. , “On the other hand, aerobic exercise and other ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Susan Binau, Founder of Soul Care Group, Inc., a 2015 Professional Woman of the Year 2Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 2Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 3Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 2Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 3Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Medical Doctor in Huntsville Reveals That Aerobic Exercise Offers Best Results in Fibromyalgia Treatment 2
... by researchers from Trinity College and the Research Institute for ... current smokers, and obtains insight into how to quit smoking ... have successfully managed to do so. Functional ... never smokers performed tasks designed to assess specific cognitive skills ...
... A motor regulatory protein can block human ovarian tumor ... new therapies to treat the disease, according to Penn ... an estimated 21,880 new cases and 13,850 deaths occurred ... most common forms of ovarian cancer and the most ...
... This release is available in German . ... play in future energy supplies? What are the elemental processes ... regeneratively in this manner? How do viruses manage to cross ... viral hosts? What constitutes a healthy thyroid gland metabolism? How ...
... racesespecially Blacksare more willing than Whites to expend personal ... lung or colorectal cancer, even if it means using ... the conclusion of a new study published early online ... American Cancer Society. Delivering quality cancer care that is ...
... Steven Reinberg HealthDay Reporter , MONDAY, April ... Tai chi may improve quality of life for people ... chi combines flowing circular movements, balance and weight-shifting, breathing ... shown to be helpful with a number of medical ...
... your brain healthy, it turns out that visiting friends, attending ... good for you as crossword puzzles. According to research ... help to prevent or delay cognitive decline in old age. ... Journal of the International Neuropsychological Society . The researchers ...
Cached Medicine News:Health News:Brain imaging demonstrates that former smokers have greater willpower 2Health News:Motor protein may offer promise in ovarian cancer treatment 2Health News:DFG establishes 13 new priority programs 2Health News:DFG establishes 13 new priority programs 3Health News:DFG establishes 13 new priority programs 4Health News:Racial differences in willingness to exhaust personal finances for life-sustaining care 2Health News:Tai Chi May Help Heart Failure Patients 2Health News:Tai Chi May Help Heart Failure Patients 3Health News:Higher levels of social activity decrease the risk of cognitive decline 2
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
The popular E2002 Utrata Capsulorhexis Forceps with fine angled sharp tips. Angled 12 mm shafts with an iris stop. Flat handle with dull finish....
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish....
Medicine Products: